Risk factors of chronic kidney disease in cisplatin-based hyperthermia intraperitoneal chemotherapy

CONCLUSION: Intraoperative use of parecoxib during cisplatin-based HIPEC emerged as a significant risk factor for postoperative CKD. Clinicians should exercise caution in prescribing parecoxib during HIPEC procedures. Additionally, maintaining intraoperative body temperature below 38.5°C might be crucial to mitigate the risk of CKD development. This study underscores the importance of identifying and preventing specific risk factors to improve long-term renal outcomes in patients undergoing cisplatin-based HIPEC.PMID:38342495 | DOI:10.1080/02656736.2024.2304250
Source: International Journal of Hyperthermia - Category: Internal Medicine Authors: Source Type: research